Poly Medicure - at an inflection point!


(Mallikarjun) #141

All leading OEMs are looking at manufacturing out of India. There are huge distribution networks that are looking at outsourcing manufacturing from India. These people are looking at Polymed - as a leading manufacturer of a basket of products

OEM vertical is our focus area. We plan to scale up this vertical significantly. As mentioned before there is interest being shown by lot of global players. Let us see what emerges.

Donald paaji will not Polymedicure ‘brand’ be diluted if they pursue OEM deals in a significant way ? Or are products ( OEM supplies) retailed under Poly medicure brand presently and will be in future ?


(Donald Francis) #142

Mallikarjun,

Please call me Donald.

For the size of a company like Poly Medicure today, its no wonder that its own brand sales are miniscule - as its spending power for creating ist own branding in global markets.

The only way it can scale will be through big-time volumes that are with the largest OEMs of Medical devices - who own brand and mindspace of doctors/hospitals. All global OEMs are trying to rationalise their cost structures by outsourcing manfacturing. So its a win-win relationship that can be created.

Poly Medicure is sure to strike a deal sooner than later with OEMs/large distributors - due to comparable quality with superior cost-structures vs the leading players. They also have the requisite USFDA approved facilities.


(Mallikarjun) #143

The only way it can scale will be through big-time volumes that are with the largest OEMs of Medical devices - who own brand and mindspace of doctors/hospitals

Completely with you… Its too difficult to break into the big league (B. Braun, BD etc)…

Hope they don’t dilute their brand by focusing too much on OEMs… Just smartly scout OEMs for knowhow and to penetrate USA…

Sincerely hope they ramp up domestic operations, exports and then OEMs (supplies) in the same order as indicated in management Q&A…

Regards

mallikarjun


(Binu) #144

Ayush, Donald and others,

From a valuation perspective, Poly medicure looks like its fully valued based on Donald’s projections for FY14 ie 17-18.

Looking at the historical PE of Poly, from July 2010 till Jan 2013 period, its been 16/17. Graph attached.

I reckon accumulation/“buy on declines” would be when the price falls below 300, thoughts?



(Mallikarjun) #145

Results Q2

NetSales - 26.9 %…Net Profit - 217 % …EPS - 5.01


(anil) #146

Results Q2

NetSales

Where did you get this info?

I cant see results on BSE.


(Mallikarjun) #147

Anil the results are on NSE…


(Manish Vachhani) #148

Results are available on NSE at the following link :

C:)Documents and Settings)Administrator)My Documents)Downloads)POLYMED_30sep2013_S (1).zip


(Manprit) #149

The correct link is:

http://www.nseindia.com/corporate/POLYMED_30sep2013_S.zip


(Rohit Ojha) #150

There has been no comment on Q2 results. It seems EPS of 18 will be very much possible. After having gone through the ARs and the management interviews, I agree that it can do very well in next 2-3 years. I have not digged into Shilpa but which one looks more undervalued at CMP? Polymed has corrected a bit and now trading near 150 DMA with low volumes.


(JatinK) #151

I agree with Rohit here.

Good chance of touching 18-19 EPS for the year.

So Poly looks attractive at 16-17 PE given mgt Q&A and past track record…


(Prasanna Sankaranarayanan) #152

The predictions were spot on. Do we have any guesses on what EPS FY15 might enjoy?


(Rudra Chowdhury) #153

Poly Med loses court battle in Spain against B. Braun

The Commercial Court no. 4 ofBarcelonahas prohibited the manufacture and/or import inSpainof safety IV catheters supplied by Poly Medicure, Ltd. (Polymed) while B. Braun’s Spanish patent ES2402727 (EP1911487) remains in force.

The case was initiated lastNovember 2013, when B. Braun became aware that a Spanish company took part in a public tender called by the health authorities of Basque Country (Osakidetza), with an offer of safety IV catheters supplied by Polymed and commercialised inEuropeby the German company Troge Medical GmbH which fell under the scope of said patent.


(Mallikarjun) #154

Thanku Rudra Shankar for the update… Seniors please chip in…

The other thing is promoters have reduced their stake very minutely from 48.7 to 48.68…


(vicky kumar) #155

hi rudra

great work…im new to this forum…i wish to know how u got hold of this news about the court verdict…i googled on polymed as search but could not get…

it would be really nice of u to guide people like us on how to get news about companies…any spl website(for pharma especially)…to know about fds approvals etc etc…to keep track when matter comes for hearing/verdict fr approvals etc…

thanks


(Utkarsh Patel) #156

Results are out.

Total income from operations 80.3 cr vs 62.99 cr

Profit from op before other income 13.48 cr vs 13.34 cr

Other income 3.74 cr vs 0.13 cr

Net profit 11.06 cr vs 8.24 cr

EPS 5.01 vs 3.75


(anil) #157

Poly med Q3 results released:

Q3 Sales at 78cr vs 77cr at Q2fy14 and 61cr in 2Qfy13

Q3 net at 11.05cr vs 11.04cr at Q2fy14 and 8.24cr in 2Qfy13

Q3 had other income of 3.7cr received from settlement with a customer.

Views?


(anil) #158

Correction:

Poly med Q3 results released:

Q3 Sales at 78cr vs 77cr at Q2fy14 and 61cr in 3Qfy13

Q3 net at 11.05cr vs 11.04cr at Q2fy14 and 8.24cr in 3Qfy13

Q3 had other income of 3.7cr received from settlement with a customer.

Views?


(Hitesh Patel) #159

Results seem broadly in line… the dip in operating profit in q3 fy 14 as compared to q2 fy 14 is mainly due to higher other expenses…(?? forex)

Company should report full year eps figures of closer to 20 per share… at cmp of around 350 it quotes at 17.5 times fy 14 figures…

Neither too cheap nor too expensive. :slight_smile:


(Rudra Chowdhury) #160

hi vicky,

you can search the company name in “Google News” and track latest updates from the companies.

Alternatively, I set up Google Alerts for all my portfolio companies where any updates/news across the world triggers an email right to your inbox. Here you won’t miss critical updates.